Aduhelm (aducanumab-avwa) was granted accelerated approval by the FDA in June 2021 despite misgivings from the agency’s Peripheral and Central Nervous System Drugs Advisory Committee.
Beyond the Ordinary Beyond the Obvious
Beyond the Ordinary Beyond the Obvious
Aduhelm (aducanumab-avwa) was granted accelerated approval by the FDA in June 2021 despite misgivings from the agency’s Peripheral and Central Nervous System Drugs Advisory Committee.
